➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
McKinsey
Moodys
Medtronic
Merck

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Aducanumab

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Aducanumab?

Aducanumab is an investigational drug.

There have been 8 clinical trials for Aducanumab. The most recent clinical trial was a Phase 1 trial, which was initiated on August 1st 2015.

The most common disease conditions in clinical trials are Alzheimer Disease, Cognitive Dysfunction, and Dementia. The leading clinical trial sponsors are Biogen and [disabled in preview].

There are four US patents protecting this investigational drug and fifteen international patents.

Recent Clinical Trials for Aducanumab
TitleSponsorPhase
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205BiogenPhase 3
A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging AbnormalitBiogenPhase 2
Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy ParticipantsBiogenPhase 1

See all Aducanumab clinical trials

Clinical Trial Summary for Aducanumab

Top disease conditions for Aducanumab
Top clinical trial sponsors for Aducanumab

See all Aducanumab clinical trials

US Patents for Aducanumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Aducanumab   Start Trial Intranasal administration of guanidinylated aminoglycosides THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA)   Start Trial
Aducanumab   Start Trial Binding-triggered transcriptional switches and methods of use thereof The Regents of the University of California (Oakland, CA)   Start Trial
Aducanumab   Start Trial Cell culture medium LA JOLLA BIOLOGICS, INC. (San Diego, CA)   Start Trial
Aducanumab   Start Trial Humanized tau antibodies in alzheimer's disease Axon Neuroscience SE (Larnaka, CY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Aducanumab

Drugname Country Document Number Estimated Expiration Related US Patent
Aducanumab World Intellectual Property Organization (WIPO) 2014159878 2033-03-13   Start Trial
Aducanumab Australia 2015348012 2034-11-19   Start Trial
Aducanumab Brazil 112017010498 2034-11-19   Start Trial
Aducanumab Canada 2966964 2034-11-19   Start Trial
Aducanumab China 107428820 2034-11-19   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
McKinsey
Moodys
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.